Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats

References

• Wang J, Wang Z, Guo F, et al. Individual and combined cardiometabolic morbidities and the subsequent risk of cardiovascular events in Chinese adults. J Clin Endocrinol Metab. 2022;107(1):1–10. doi: 10.1210/clinem/dgab609.
   PubMed Web of Science ®Google Scholar
• Hirohama D, Fujita T. Evaluation of the pathophysiological mechanisms of salt-sensitive hypertension. Hypertens Res. 2019;42(12):1848–1857. doi: 10.1038/s41440-019-0332-5.
   PubMed Web of Science ®Google Scholar
• Iatrino R, Manunta P, Zagato L. Salt sensitivity: challenging and controversial phenotype of primary hypertension. Curr Hypertens Rep. 2016;18(9):70. doi: 10.1007/s11906-016-0677-y.
   PubMed Web of Science ®Google Scholar
• Drenjančević-Perić I, Jelaković B, Lombard JH, et al. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34(1):1–11. doi: 10.1159/000320387.
   PubMed Web of Science ®Google Scholar
• Jama HA, Beale A, Shihata WA, et al. The effect of diet on hypertensive pathology: is there a link via gut microbiota-driven immunometabolism? Cardiovasc Res. 2019;115(9):1435–1447. doi: 10.1093/cvr/cvz091.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15(1):20–32. doi: 10.1038/nrcardio.2017.120.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. doi: 10.1186/s40168-016-0222-x.
   PubMed Web of Science ®Google Scholar
• de Araújo Henriques Ferreira G, Magnani M, Cabral L, et al. Potentially probiotic Limosilactobacillus fermentum fruit-derived strains alleviate cardiometabolic disorders and gut microbiota impairment in male rats fed a high-fat diet. Probiotics Antimicrob Proteins. 2022;14(2):349–359. doi: 10.1007/s12602-021-09889-y.
   PubMed Web of Science ®Google Scholar
• Poll BG, Cheema MU, Pluznick JL. Gut microbial metabolites and blood pressure regulation: focus on SCFAs and TMAO. Physiology (Bethesda). 2020;35(4):275–284. doi: 10.1152/physiol.00004.2020.
   PubMed Web of Science ®Google Scholar
• Cosola C, Rocchetti MT, Cupisti A, et al. Microbiota metabolites: pivotal players of cardiovascular damage in chronic kidney disease. Pharmacol Res. 2018;130:132–142. doi: 10.1016/j.phrs.2018.03.003.
   PubMed Web of Science ®Google Scholar
• Tokarek J, Budny E, Saar M, et al. Does the composition of gut microbiota affect hypertension? Molecular mechanisms involved in increasing blood pressure. Int J Mol Sci. 2023;24(2):1377. doi: 10.3390/ijms24021377.
   PubMed Web of Science ®Google Scholar
• Rayego-Mateos S, Valdivielso JM. New therapeutic targets in chronic kidney disease progression and renal fibrosis. Expert Opin Ther Targets. 2020;24(7):655–670. doi: 10.1080/14728222.2020.1762173.
   PubMed Web of Science ®Google Scholar
• Sueyoshi M, Fukunaga M, Mei M, et al. Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin Exp Nephrol. 2019;23(7):908–919. doi: 10.1007/s10157-019-01727-4.
   PubMed Web of Science ®Google Scholar
• Tanada Y, Okuda J, Kato T, et al. The metabolic profile of a rat model of chronic kidney disease. PeerJ. 2017;5:e3352. doi: 10.7717/peerj.3352.
   PubMed Web of Science ®Google Scholar
• Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension. 1994;23(2):195–199. doi: 10.1161/01.hyp.23.2.195.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Mandal J, Cheng X, et al. Diurnal timing dependent alterations in gut microbial composition are synchronously linked to salt-sensitive hypertension and renal damage. Hypertension. 2020;76(1):59–72. doi: 10.1161/HYPERTENSIONAHA.120.14830.
   PubMed Web of Science ®Google Scholar
• Sokolov V, Yakovleva T, Chu L, et al. Differentiating the sodium-glucose cotransporter 1 inhibition capacity of canagliflozin vs. Dapagliflozin and Empagliflozin using quantitative systems pharmacology modeling. CPT Pharmacometrics Syst Pharmacol. 2020;9(4):222–229. doi: 10.1002/psp4.12498.
   PubMedGoogle Scholar
• Ho H-J, Kikuchi K, Oikawa D, et al. SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure. Physiol Rep. 2021;9(24):e15092. doi: 10.14814/phy2.15092.
   PubMed Web of Science ®Google Scholar
• Mishima E, Fukuda S, Kanemitsu Y, et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am J Physiol Renal Physiol. 2018;315(4):F824–F833. doi: 10.1152/ajprenal.00314.2017.
   PubMed Web of Science ®Google Scholar
• Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–857. doi: 10.1038/s41587-019-0209-9.
   PubMed Web of Science ®Google Scholar
• Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–583. doi: 10.1038/nmeth.3869.
   PubMed Web of Science ®Google Scholar
• DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72(7):5069–5072. doi: 10.1128/AEM.03006-05.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang X, Wang J, et al. Metabonomics approach to assessing the metabolism variation and endoexogenous metabolic interaction of ginsenosides in cold stress rats. J Proteome Res. 2016;15(6):1842–1852. doi: 10.1021/acs.jproteome.6b00015.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• Leoncini G, Russo E, Bussalino E, et al. SGLT2is and renal protection: from biological mechanisms to real-world clinical benefits. Int J Mol Sci. 2021;22(9):4441. doi: 10.3390/ijms22094441.
   PubMed Web of Science ®Google Scholar
• Isidto R, Danguilan R, Naidas O, et al. Emerging role of sodium-glucose co-transporter 2 inhibitors for the treatment of chronic kidney disease. Int J Nephrol Renovasc Dis. 2023;16:43–57. doi: 10.2147/IJNRD.S387262.
   PubMed Web of Science ®Google Scholar
• Mell B, Jala VR, Mathew AV, et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics. 2015;47(6):187–197. doi: 10.1152/physiolgenomics.00136.2014.
   PubMed Web of Science ®Google Scholar
• Adnan S, Nelson JW, Ajami NJ, et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genomics. 2017;49(2):96–104. doi: 10.1152/physiolgenomics.00081.2016.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Nelson E, Chu PY, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. CIRCULATION. 2017;135(10):964–977. doi: 10.1161/CIRCULATIONAHA.116.024545.
   PubMed Web of Science ®Google Scholar
• Abais-Battad JM, Saravia FL, Lund H, et al. Dietary influences on the Dahl SS rat gut microbiota and its effects on salt-sensitive hypertension and renal damage. Acta Physiol (Oxf). 2021;232(4):e13662. doi: 10.1111/apha.13662.
   PubMed Web of Science ®Google Scholar
• Robles-Vera I, de la Visitación N, Toral M, et al. Changes in gut microbiota induced by doxycycline influence in vascular function and development of hypertension in DOCA-salt rats. Nutrients. 2021;13(9):2971. doi: 10.3390/nu13092971.
   PubMed Web of Science ®Google Scholar
• Hollister Emily B, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. GASTROENTEROLOGY. 2014;146(6):1449–1458. doi: 10.1053/j.gastro.2014.01.052.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Kashiwagi S, et al. Changes in the gut microbiota are associated with hypertension, hyperlipidemia, and type 2 diabetes mellitus in Japanese subjects. Nutrients. 2020;12(10):2996. doi: 10.3390/nu12102996.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo controlled study. Diabetes Care. 2013;36(8):2154–2161. doi: 10.2337/dc12-2391.
   PubMed Web of Science ®Google Scholar
• Wang L, Liang C, Song X, et al. Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1256292. doi: 10.3389/fendo.2023.1256292.
   PubMedGoogle Scholar
• Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N‐oxide, a flavin‐containing monooxygenase 3 (FMO3)‐mediated host‐microbiome metabolic axis implicated in health and disease. Drug Metab Dispos. 2016;44(11):1839–1850. doi: 10.1124/dmd.116.070615.
   PubMed Web of Science ®Google Scholar
• Wiest R, Chen F, Cadelina G, et al. Effect of lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci. 2003;48(6):1136–1141. doi: 10.1023/a:1023729115659.
   PubMed Web of Science ®Google Scholar
• Vijay A, Astbury S, Panayiotis L, et al. Dietary interventions reduce traditional and novel cardiovascular risk markers by altering the gut microbiome and their metabolites. Front Cardiovasc Med. 2021;8:691564. doi: 10.3389/fcvm.2021.691564.
   PubMed Web of Science ®Google Scholar
• Liu J, An N, Ma C, et al. Correlation analysis of intestinal flora with hypertension. Exp Ther Med. 2018;16(3):2325–2330. doi: 10.3892/etm.2018.6500.
   PubMed Web of Science ®Google Scholar
• Guo H, Hao Y, Fan X, et al. Administration with quinoa protein reduces the blood pressure in spontaneously hypertensive rats and modifies the fecal microbiota. Nutrients. 2021;13(7):2446. doi: 10.3390/nu13072446.
   PubMed Web of Science ®Google Scholar
• Wan C, Chen S, Zhao K, et al. Serum untargeted metabolism reveals the mechanism of L. plantarum ZDY2013 in alleviating kidney injury induced by high-salt diet. Nutrients. 2021;13(11):3920. doi: 10.3390/nu13113920.
   PubMed Web of Science ®Google Scholar
• Robles-Vera I, de la Visitación N, Toral M, et al. Probiotic Bifidobacterium breve prevents DOCA-salt hypertension. Faseb J. 2020;34(10):13626–13640. doi: 10.1096/fj.202001532R.
   PubMedGoogle Scholar
• Liu X, Mao B, Gu J, et al. Blautia-a new functional genus with potential probiotic properties? Gut Microbes. 2021;13(1):1–21. doi: 10.1080/19490976.2021.1875796.
   Web of Science ®Google Scholar
• Ozato N, Yamaguchi T, Mori K, et al. Two Blautia species associated with visceral fat accumulation: a one-year longitudinal study. Biology (Basel). 2022;11(2):318. doi: 10.3390/biology11020318.
   PubMedGoogle Scholar
• Tosaki T, Kamiya H, Himeno T, et al. Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes. Intern Med. 2017;56(6):597–604. doi: 10.2169/internalmedicine.56.7196.
   PubMed Web of Science ®Google Scholar
• Koppe L, Fouque D, Soulage CO. The role of gut microbiota and diet on uremic retention solutes production in the context of chronic kidney disease. Toxins (Basel). 2018;10(4):155. doi: 10.3390/toxins10040155.
   PubMed Web of Science ®Google Scholar
• Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch. 2020;472(3):303–320. doi: 10.1007/s00424-020-02352-x.
   PubMed Web of Science ®Google Scholar
• Barrios C, Beaumont M, Pallister T, et al. Gut-microbiota-metabolite axis in early renal function decline. PLoS One. 2015;10(8):e0134311. doi: 10.1371/journal.pone.0134311.
   PubMed Web of Science ®Google Scholar
• Wen D, Zheng Z, Surapaneni A, et al. Metabolite profiling of CKD progression in the chronic renal insufficiency cohort study. JCI Insight. 2022;7(20):e161696. doi: 10.1172/jci.insight.161696.
   Web of Science ®Google Scholar
• Uehara T, Horinouchi A, Morikawa Y, et al. Identification of metabolomic biomarkers for drug-induced acute kidney injury in rats. J Appl Toxicol. 2014;34(10):1087–1095. doi: 10.1002/jat.2933.
   PubMed Web of Science ®Google Scholar
• Kamiński TW, Pawlak K, Karbowska M, et al. Indoxyl sulfate – the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol. 2017;18(1):35. doi: 10.1186/s12882-017-0457-1.
   PubMedGoogle Scholar
• Roth W, Zadeh K, Vekariya R, et al. Tryptophan metabolism and gut-brain homeostasis. Int J Mol Sci. 2021;22(6):2973. doi: 10.3390/ijms22062973.
   PubMed Web of Science ®Google Scholar
• Zinellu A, Sotgia S, Mangoni AA, et al. Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutr Metab Cardiovasc Dis. 2015;25(2):153–159. doi: 10.1016/j.numecd.2014.11.004.
   PubMed Web of Science ®Google Scholar
• Kim SM, Song IH. The clinical impact of gut microbiota in chronic kidney disease. Korean J Intern Med. 2020;35(6):1305–1316. doi: 10.3904/kjim.2020.411.
   PubMed Web of Science ®Google Scholar
• Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. mBio. 2014;5(2):e00889. doi: 10.1128/mBio.00889-14.
   PubMed Web of Science ®Google Scholar
• Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–1499. doi: 10.1053/j.gastro.2014.02.009.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li Q, Liu F, et al. Lycoperoside H protects against diabetic nephropathy via alteration of gut microbiota and inflammation. J Biochem Mol Toxicol. 2022;36(12):e23216. doi: 10.1002/jbt.23216.
   PubMed Web of Science ®Google Scholar
• Mitrović M, Stanković-Popović V, Tolinački M, et al. The impact of synbiotic treatment on the levels of gut-derived uremic toxins, inflammation, and gut microbiome of chronic kidney disease patients-a randomized trial. J Ren Nutr. 2022;33(2):278–288. doi: 10.1053/j.jrn.2022.07.008.
   PubMed Web of Science ®Google Scholar
• Hata S, Okamura T, Kobayashi A, et al. Gut microbiota changes by an SGLT2 inhibitor, Luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db/db mice. Nutrients. 2022;14(17):3531. doi: 10.3390/nu14173531.
   PubMed Web of Science ®Google Scholar
• Mangutov EO, Alieva AA, Kharseeva GG, et al. Corynebacterium spp.: relationship of pathogenic properties and antimicrobial resistance. Klin Lab Diagn. 2022;67(9):519–524. doi: 10.51620/0869-2084-2022-67-9-519-524.
   PubMedGoogle Scholar
• Tsuge Y, Matsuzawa H. Recent progress in production of amino acid-derived chemicals using Corynebacterium glutamicum. World J Microbiol Biotechnol. 2021;37(3):49. doi: 10.1007/s11274-021-03007-4.
   PubMed Web of Science ®Google Scholar